Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis.
(2018) Patient Related Outcome Measures — Vol. 9, p. 1-10 (2018)
Files
Longtermsafety.pdf
Open Access - Adobe PDF
- 236.22 KB
Details
- Authors
- Abstract
- With a growing number of disease-modifying therapies becoming available for relapsing multiple sclerosis, there is an important need to gather real-world evidence data regarding long-term treatment effectiveness and safety in unselected patient populations. Although not providing as high a level of evidence as randomized controlled trials, and prone to bias, real-world studies from observational studies or registries nevertheless provide crucial information on real-world outcomes of a given therapy. In addition, evaluation of treatment satisfaction and impact on quality of life are increasingly regarded as complementary outcome measures. Fingolimod was the first oral disease-modifying therapy approved for relapsing multiple sclerosis. This review aims to summarize current knowledge on the long-term effectiveness and safety outcomes of multiple sclerosis patients on fingolimod. Impact on treatment satisfaction and quality of life will be discussed according to available data.
- Affiliations
Citations
Druart, C., El Sankari, S., & Van Pesch, V. (2018). Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. Patient Related Outcome Measures, 9, 1-10. https://doi.org/10.2147/PROM.S122401 (Original work published 2018)